Azarin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azarin

Azarin is a synthetic, prescription-only medication whose active component is Azathioprine, a compound primarily classified as an immunosuppressive agent. This medication is fundamentally used to provide long-term maintenance therapy by regulating the body's immune response in chronic conditions where it is overactive.

Property Description
Active ingredient Azathioprine
Form Oral tablet, Solution for injection
Pharmacological class Immunosuppressive agent, Antimetabolite
Common use Modulating chronic immune activity
Origin Synthetic compound

What is Azarin, and What Type of Medicine is It?

Azathioprine is categorized as both a cytotoxic agent and an antimetabolite, placing it within a class of drugs that interfere with cellular functions. The medicine’s identity as a purine analog and a thiopurine reflects its chemical structure, which mimics the natural purine building blocks necessary for cell multiplication. This pharmacological identity is clinically recognized for its efficacy in controlling severe immune-mediated conditions, confirming the drug is reliably used to dampen an overactive immune system. Azathioprine is also known under other popular brand names, such as Imuran and Azasan, sharing the same core mechanism.

Composition and Available Forms of Azathioprine

The composition of Azarin is based on its single active ingredient, Azathioprine, which is a synthetic compound that acts as a prodrug. The medication is most frequently supplied as an oral solid form (tablet) for systemic, long-term treatment, though it is also available as a solution for intravenous administration. The availability of different forms ensures flexible administration for patients who require either long-term maintenance or initial stabilization. A differentiating factor of Azathioprine is its unique metabolic pathway compared to other immunosuppressants.

The General Therapeutic Purpose of Azarin

The fundamental therapeutic purpose of Azarin is to suppress chronic, harmful immune activity by inhibiting the rapid proliferation of immune cells, specifically lymphocytes. By interfering with their growth, the drug helps to control the excessive immune response and reduce the severity of immune-mediated inflammation. A typical use scenario involves its application as a cornerstone agent in long-term treatment protocols designed to manage autoimmune diseases or to help prevent the body from rejecting a transplanted organ. The ultimate goal of this medication is to establish long-term immunological balance.

What side effects are possible with Azarin?

Possible Side Effects and Safety Information

The officially documented safety profile of Azarin, which contains Azathioprine, is largely determined by its action as an immunosuppressive and cytotoxic agent, as classified by regulatory authorities like the FDA and EMA. All adverse reactions and safety statements are derived directly from regulatory prescribing information.


Frequency-Classified Adverse Reactions

The most frequently classified adverse reactions involve the blood and immune system. Very common reactions (occurring in 10% or more of patients) include leukopenia (low white blood cell count) and infections, particularly in organ transplant recipients. Common reactions (occurring in 1% to less than 10% of patients) include thrombocytopenia (low platelet count), anemia, nausea, vomiting, and signs of liver toxicity.


Serious Adverse Reactions and Safety Constraints

The regulatory label contains a Boxed Warning highlighting the increased risk of malignancy (cancers), including lymphomas, which is associated with chronic immunosuppression. Rare, but serious, reactions include severe myelosuppression (bone marrow depression), which can be life-threatening, and severe hepatotoxicity (liver damage).

Safety notes explicitly mention that individuals with genetically reduced or absent activity of the TPMT or NUDT15 enzymes face a profoundly increased risk of this severe myelosuppression. Due to this hematologic risk, mandatory and frequent blood monitoring is required. The label also specifies that drug interactions, such as concomitant use with allopurinol or febuxostat, can dramatically increase the risk of toxicity.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Azarin (Azathioprine) is primarily associated with the risk of severe, delayed bone marrow suppression (myelotoxicity). Acute effects may include nausea, vomiting, and diarrhea. However, the most life-threatening consequences, such as pancytopenia (low count of all blood cell types), are delayed, typically reaching their nadir 9 to 19 days following exposure. Individuals with a documented deficiency in the TPMT or NUDT15 enzymes are at a substantially increased risk for severe toxicity.

When to seek immediate medical help

Government health authorities mandate immediate contact with emergency services (e.g., 911) if the victim has collapsed, had a seizure, has trouble breathing, or cannot be awakened. In any overdose situation, the poison control helpline should be called. Patients must also immediately report any signs of impending myelosuppression, such as fever, unexpected bruising, bleeding, or ulceration of the throat.

Management and Monitoring

There is no specific antidote known for Azathioprine. Management is supportive, and the official label requires frequent monitoring of blood count and hepatic function. In severe cases, the drug is partially dialysable, and dialysis may be considered as a procedural intervention.

Therapeutic Uses of Azarin

What Azarin Treats: Main Uses and Benefits

Azarin, which contains the active ingredient Azathioprine, is commonly used to help manage chronic, severe conditions by managing the systemic imbalance associated with chronic conditions. It is generally applied across domains where additional symptomatic support is needed. Its therapeutic applications include use in the context of organ transplantation and supporting the management of symptoms related to severe rheumatoid arthritis.

The medication is relevant for managing groups of symptoms that may become intense or disruptive in conditions like Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), and Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis). This broad therapeutic approach supports the patient during difficult episodes by easing distress and is applied when symptoms create noticeable physiological strain.

“This therapeutic support is commonly used to help prevent the body's immune response to a transplanted organ.”

The primary patient benefit supports the patient's general well-being and contributes to improved day-to-day comfort during symptomatic periods. It is also considered relevant in clinical settings where additional symptomatic support is needed for severe, treatment-resistant manifestations.


Quick Fact: Symptomatic Support in Inflammatory States Azarin is commonly used to help with groups of symptoms (e.g., symptoms related to physical discomfort or inflammatory or irritative states) that create noticeable physiological strain and interfere with daily functioning.

Eligibility and Restrictions for Use

Who Must Not Use Azarin?

Azarin is contraindicated in patients with a known hypersensitivity to the medication or to its active metabolite, Mercaptopurine. Regulatory labeling also prohibits use in individuals with documented severe bone marrow suppression and during pregnancy when treating conditions like Rheumatoid Arthritis.


Populations Requiring Caution

The medicine is used under restricted circumstances in several patient groups. Individuals with severe hepatic (liver) or renal (kidney) impairment require caution. Use is further limited by specific genetic profiles, such as TPMT or NUDT15 deficiency, which necessitate strict monitoring. Additionally, use in pregnant women and those who are breastfeeding is generally not recommended.


Age and General Eligibility

Use is established for adults and is permitted in pediatric patients only for specific approved indications, such as severe Rheumatoid Arthritis, typically from six years of age. Geriatric patients must be treated with caution due to potential age-related decline in organ function.

What should I know about interactions with other medicines?

The interaction profile of Azarin is primarily structured by specific metabolic constraints and documented additive risks defined in regulatory labeling.

Prohibition and Exposure-Related Restrictions

Co-administration of Azarin with Mercaptopurine and all Live Vaccines is contraindicated by regulatory agencies. Substances that inhibit the Xanthine Oxidase (XO) enzyme, such as Allopurinol, are highly regulated because they interfere with the inactivation pathway for Azarin’s active metabolite. This metabolic inhibition causes a major increase in active metabolite exposure and necessitates a substantial dose constraint when co-administered. The combination with Febuxostat is also classified as not recommended for the same exposure-altering risk.

Additive and Pharmacodynamic Effects

Regulatory documents specify additive risks with agents that have independent haematological effects. ACE Inhibitors and various Cytostatic Agents are documented to increase the risk of myelosuppression. The profile also includes specific pharmacodynamic effects, noting that Azarin antagonizes the effect of non-depolarizing neuromuscular blocking agents and potentiates depolarizing agents. The inhibition of the anticoagulant effect of agents like Warfarin is also reported in official labeling.

Population-Specific Caution

The risk of severe toxicity from metabolic interactions with XO inhibitors is officially stated to be heightened in patients with genetically determined low or absent TPMT activity.

Mechanism of Action

Azarin (Azathioprine) is a synthetic antimetabolite prodrug whose mechanism involves the inhibition of immune cell proliferation through metabolic interference. The drug first converts into its active metabolite, 6-Mercaptopurine (6-MP). These metabolites inhibit crucial enzymes, such as IMPDH and ATase, in the purine de novo synthesis pathway. This action constrains the growth of rapidly proliferating cells, especially T- and B-lymphocytes. The most potent metabolites, 6-Thioguanine Nucleotides (6-TGNs), are incorporated directly into the DNA and RNA, causing structural damage, cell cycle arrest, and programmed cell death (apoptosis) via signaling proteins like Rac1. The resulting systemic reduction in the lymphocyte population is a key physiological effect that modulates the intensity of the cellular immune activity. The mechanism's efficiency is constrained by the genetically variable TPMT enzyme activity and the time required for existing immune cells to be depleted; therefore, the maximum functional effect on the cellular population is inherently delayed.

Dosage and Administration Information

How to Use Azarin: Official Administration Guidelines

Azarin (Azathioprine) is administered through one of two official routes: orally, typically as a tablet, or intravenously (IV) via injection. The oral route is the standard method for long-term maintenance therapy, while the intravenous solution is generally reserved for initial stabilization in a supervised clinical setting before transitioning the patient to the oral form.

Dosing protocols are primarily weight-based, calculated in milligrams per kilogram of body weight per day (mg/kg/day). For transplantation maintenance, the typical daily dose ranges from 1 to 3 mg/kg/day. For other approved conditions, the starting dose is often 1 mg/kg/day, with a maximum limit generally not exceeding 2.5 mg/kg/day. The total prescribed daily amount is usually taken once daily or in two divided doses.

Administration Condition Official Instruction
Intake with Food Recommended to be taken with or immediately after food to mitigate potential gastrointestinal discomfort.
Dose Adjustment Dosages for older adults and patients with renal or hepatic impairment should be administered at the lower end of the established range.
Course Duration Therapy is often long-term or indefinite for organ transplantation; for autoimmune conditions, a minimum of 12 weeks is required to assess therapeutic response.

The medication requires adherence to a strict daily schedule. Specific formulations, such as film-coated tablets, must not be divided or crushed, maintaining the procedural integrity of the formulation.

Recent Clinical Evidence

Research evidence / Overview of studies for Azarin (Azathioprine)

This section summarizes the official research evidence for Azathioprine, focusing on the types of clinical studies, the populations examined, and the outcomes measured, as documented by regulatory and peer-reviewed sources. Research findings describe group patterns and contribute to the broader evidence landscape, but research does not determine whether an individual will respond similarly.

Evidence for Use in Kidney Transplantation: Preventing Organ Rejection

Research for Azathioprine in transplantation is documented by decades of observational data and a history of controlled trials. These studies focused primarily on adult kidney transplant recipients. Researchers examined outcomes such as patient survival rates and the long-term survival of the transplanted organ (graft survival). Regulatory summaries describe patterns observed when the medicine was used alongside other agents in settings relevant to organ transplantation.

Evidence for Use in Rheumatoid Arthritis (RA)

Research for Azathioprine in Rheumatoid Arthritis (RA) was evaluated in randomized controlled trials (RCTs) and systematic reviews. These studies explored how the medicine was evaluated in adult patients who have chronic, active, or severe RA. The trials monitored change in disease activity, focusing on counts of tender and swollen joints and tracking outcomes related to physical discomfort and daily functioning. Some trials described patterns suggesting the monitoring of corticosteroid dose reduction as an outcome (steroid-sparing effect).

Areas of Uncertainty and Research Gaps

The evidence highlights several areas where research is ongoing or where data remain insufficient. Follow-up durations were limited in some trials, particularly regarding the long-term impact on functional decline or structural damage in conditions like Rheumatoid Arthritis. Sample sizes were modest in some foundational studies, affecting the certainty of generalizing findings to larger populations. Furthermore, comparative evidence is lacking for some outcomes when comparing Azathioprine directly against the newest available therapeutic options.

Key Studies & References

  1. NIH MedlinePlus Drug Information on Azathioprine (Used for common uses)
  2. Azathioprine for rheumatoid arthritis (Cochrane Review)
  3. Thiopurines for induction of remission in ulcerative colitis (Cochrane Review)

Frequently Asked Questions (FAQ)

Common questions about Azarin (FAQ)


Q: Is Azarin a type of antibiotic or something else?

Azarin is not classified as an antibiotic. According to official product information, it belongs to a class of medicines known as immunosuppressive agents and antimetabolites. Its purpose is to modulate or reduce the activity of the body’s immune system.

Q: Can Azarin affect sleep or cause insomnia?

Official safety documents do not commonly list insomnia or sleep problems as frequent side effects. However, some regulatory descriptions have noted the occurrence of general malaise, headache, or dizziness, particularly when a patient is starting the medicine.

Q: What if I accidentally miss a dose of Azarin?

Regulatory guidance describes the recommended procedure if one dose is missed: to take it as soon as it is remembered unless it is nearly time for the next scheduled dose. Official information notes that two doses should not be taken to make up for one missed dose.

Q: Are there different forms of Azarin (e.g., tablet, liquid)?

Yes, the medicine is supplied in more than one form. The most common form is the oral tablet for long-term use. There is also a solution for injection, which is typically reserved for initial stabilization in a supervised clinical setting before a patient transitions to the tablet.

Q: What kind of monitoring is usually required when taking Azarin?

Due to the medicine's potential to affect the blood and liver, mandatory and frequent blood monitoring is required throughout treatment for the purpose of ongoing surveillance. This includes checking blood cell counts and monitoring liver function tests.

Q: Why do people sometimes say Azarin is hard to tolerate?

Tolerance concerns are frequently related to common side effects involving the digestive system, such as nausea and vomiting. Official prescribing information describes that taking the medicine with or immediately after food may help to mitigate these common gastrointestinal effects.

Q: Does Azarin have any common drug-drug interactions I should be aware of?

Regulatory labeling highlights several specific interactions. Of particular note are Xanthine Oxidase inhibitors (like allopurinol), which necessitates a substantial dose constraint when co-administered. Warnings are also provided against combining the medicine with all types of live vaccines.

Q: How quickly should Azarin start to work?

The therapeutic effect of this medicine is not immediate, as it works by gradually affecting the immune system. For many approved conditions, official patient information indicates that it may take up to 8 to 12 weeks, or a few months, before a patient begins to notice an improvement.

Q: Can Azarin cause weight gain or weight loss?

Weight gain is not commonly described in official regulatory lists of side effects. However, weight loss has been reported as a less common side effect. Loss of appetite (anorexia) is listed as a very common effect.

Q: How long do most people take Azarin for?

The duration of treatment is often long-term or indefinite, especially for patients receiving the medicine for organ transplantation maintenance. For other conditions, official guidance suggests that continuous treatment may be needed for at least two years after a good clinical response is achieved.

Q: Do I need to change my diet while taking Azarin?

Official information indicates that a patient can generally eat and drink normally while taking this medicine. The key instruction is to take the medicine with or immediately after food to reduce stomach upset. Regulatory information notes that the medicine should not be taken at the same time as milk or dairy products.

Q: Is Azarin a high-risk medication?

Regulatory documents include a Boxed Warning that highlights serious risks associated with chronic immunosuppression. These risks include an increased chance of certain malignancies (cancers) and potentially life-threatening bone marrow depression. Monitoring is required to manage these serious risks.

Q: Are there any specific foods that interact badly with Azarin?

The main specific food restriction described in official patient information is related to the timing of intake. Regulatory information notes that the medicine should not be taken at the same time as milk or dairy products, as this may potentially reduce the absorption of the medicine.

Q: Is it normal to feel a little dizzy when starting Azarin?

Dizziness and lightheadedness have been reported as possible side effects. These effects may be more noticeable when first starting treatment or when the dosage is changed.

Q: Can Azarin affect my ability to drive or operate machinery?

Official safety information notes that individuals should be cautious about driving or operating machinery until it is known how the medicine affects them. This relates to the potential for side effects such as dizziness or headache.

Q: What is the average time before I can expect to see full results from Azarin?

As a slowly acting medicine, the full therapeutic response is not immediate. For conditions like Rheumatoid Arthritis, full results are typically expected to be seen within 8 to 12 weeks or after several months of continuous treatment.

Q: Can Azarin cause allergic reactions?

Yes, official safety documents describe hypersensitivity reactions, which are forms of allergic reactions, as a possible adverse effect. Regulatory information notes that immediate cessation of the medicine is typically required if signs of a severe hypersensitivity reaction are observed.

Q: What is the recommended period to wait after taking Azarin before drinking alcohol?

While alcohol is not listed as a contraindication in major interaction documents, caution may be advised by healthcare providers. This is because the medicine has the potential to affect the liver, and alcohol may contribute to liver burden.

Q: Why is Azarin sometimes used in combination with other treatments?

Azarin is commonly used as a cornerstone agent alongside other treatments, such as corticosteroids or other immunosuppressants. This combination approach is often necessary in long-term protocols designed to manage severe immune conditions and is studied for its use in minimizing the risk of organ rejection.

Q: What is the typical patient profile who benefits most from Azarin?

Research evidence for this medicine focuses primarily on, and clinical use is established for, adult patients who have received a kidney transplant. It is also commonly used for adult patients with chronic, active, or severe Rheumatoid Arthritis.

Q: Do I need any special tests before starting Azarin?

Yes, mandatory blood testing is typically required before starting treatment. This testing is often used to measure the activity level of the TPMT enzyme (an enzyme involved in drug metabolism), which is described in regulatory documents as a factor influencing an individual's risk for severe side effects.

Q: What kind of studies have been done on Azarin?

Research evidence includes decades of observational data and randomized controlled trials (RCTs). These studies focused on outcomes such as patient survival, graft survival, and changes in disease activity, like the count of tender and swollen joints.

Q: Are there any limitations on physical activity while taking Azarin?

Due to the medicine's risk of causing low blood cell counts, which can increase the risk of bruising or bleeding, some regulatory information suggests that individuals should be cautious. This is particularly relevant for activities where there is a high potential for injury.

Q: What does the research say about Azarin's effectiveness for its approved use?

Research findings describe group patterns and outcomes that contribute to the overall evidence base. These studies tracked measures related to patient survival, organ graft survival, and the reduction of symptoms, such as the count of swollen and tender joints for its approved uses.

Q: Is the long-term safety of Azarin well established?

The safety profile for chronic use is documented in regulatory warnings. These warnings mention an increased risk of malignancy (cancers), including lymphomas, which is associated with chronic immunosuppression. Official prescribing information states that therapy should be maintained at the lowest effective levels.

Q: Is there a generic version of Azarin available?

Yes, the active ingredient, Azathioprine, is an established compound that is available under various brand names. Generic forms of the medicine are commonly manufactured and used in clinical practice.

How should Azarin be stored and disposed of?

Storage Requirements

Azarin (Azathioprine) tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container, tightly closed, and protected from light and excess moisture. It is mandatory to store the medication in a location that is out of the sight and reach of children.

Handling and Disposal

As a cytotoxic agent, Azathioprine tablets should not be divided, crushed, or broken. Unused or expired medication must be disposed of properly. The drug should not be flushed down the toilet or thrown into wastewater. The preferred method of disposal is through a drug take-back program. If no program is available, the product should be mixed with an undesirable substance (e.g., dirt) and placed in a sealed container before being discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azarin found in:

A-Z Index: